Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase

Name: Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase
Published: 2025
License: Public Domain

Federal University of Latin American Integration · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

alzheimer-s-disease

alzheimer disease (ad), alzheimer's disease, cannabidiol (cbd), tetrahydrocannabinol (thc), open label, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase

Related documents